After initial diagnostic workup, What are the clinical findings?
--If Solitary plasmacytoma, Perform primary treatment, either radiation therapy with the possibility of surgery or consider a clinical trial. Afterwards, have a follow-up interval for every 3–6 months to keep track of: CBC, differential, platelet count. Serum chemistry for creatinine, albumin, and corrected calcium. Also keep track of tests as needed: Serum quantitative immunoglobulins, SPEP, with SIFE. 24-h urine for total protein and UPEP with UIFE. Serum FLC assay. Serum LDH and beta-2 microglobulin. Bone marrow aspirate and biopsy. All plasmacytomas should be imaged yearly, preferably with the same technique used at diagnosis, for at least 5 years. After, identify if primary progressive or if there is a response followed by progression. Is there a response followed by progression or is there primary progressive?
----If Yes, Restage with myeloma workup and obtain clinical findings presented as multiple myeloma. Perform myeloma therapy, beginning with Is the patient a transplant candidate?
------If Yes, Is the patient frail?
--------If No (frail score <2), Does the patient have either renal insufficiency or peripheral neuropathy?
----------If No, Is the patient standard or high risk?
------------If Standard risk, The treatments for the patient are Bortezomib/Lenalidomide/Dexamethasone combination or Carfilzomib/Lenalidomide/Dexamethasone or Carfilzomib/Lenalidomide/Bortezomib/Dexamethasone or Ixazomib/Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
--------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
--------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
----------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
----------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
--------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
--------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
----------------------If No, Patient is treated.
----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
--------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
--------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
----------------------If No, Patient is treated.
----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
------------If High Risk, The treatments for the patient are Daratumumab/Carfilzomib/Lenalidomide/Dexamethasone or Daratumumab/Cyclophosphamide/Bortezomib/Dexamethasone or Daratumumab/Bortezomib/Thalidomide/Dexamethasone or VTD-PACE. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
--------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
--------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
----------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
----------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
--------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
--------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
----------------------If No, Patient is treated.
----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
--------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
--------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
----------------------If No, Patient is treated.
----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
----------If Yes, Does the patient have acute renal insufficiency or have chronic renal insufficiency and/or peripheral neuropathy?
------------If Chronic Renal insufficiency and/or Peripheral Neuropathy, The treatments for the patient are Carfilzomib/Cyclophosphamide/Dexamethasone or Ixazomib/Cyclophosphamide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
--------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
--------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
----------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
----------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
--------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
--------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
----------------------If No, Patient is treated.
----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
--------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
--------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
----------------------If No, Patient is treated.
----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
------------If Acute Renal Insufficiency, The initial treatment for the patient is Bortezomib/Cyclophosphamide/Dexamethasone. After improvement of the renal function, the treatment for the patient is Bortezomib/Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
--------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
--------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
----------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
----------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
--------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
--------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
----------------------If No, Patient is treated.
----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
--------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
--------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
----------------------If No, Patient is treated.
----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
--------If Yes (frail score >=2), The treatments for the patient are Bortezomib/Dexamethasone or Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
----------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
----------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
--------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
----------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
----------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
------------------If No, Patient is treated.
------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
--------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
----------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
----------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
------------------If No, Patient is treated.
------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
------If No, Is the patient frail?
--------If Yes (frail score >=2), The treatments for the patient are Bortezomib/Dexamethasone or Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
----------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
----------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
--------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
----------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
----------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
------------------If No, Patient is treated.
------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
--------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
----------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
----------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
------------------If No, Patient is treated.
------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
--------If No (frail score <2), Does the patient have either renal insufficiency or peripheral neuropathy?
----------If No, The treatments for the patient are Bortezomib/Lenalidomide/Dexamethasone or Daratumumab/Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
--------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
--------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
----------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
--------------------If No, Patient is treated.
--------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
----------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
--------------------If No, Patient is treated.
--------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
----------If Yes, Does the patient have acute renal insufficiency or have chronic renal insufficiency and/or peripheral neuropathy?
------------If Chronic Renal insufficiency and/or Peripheral Neuropathy, The treatments for the patient are Carfilzomib/Cyclophosphamide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
--------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
--------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
----------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
----------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
--------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
--------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
----------------------If No, Patient is treated.
----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
--------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
--------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
----------------------If No, Patient is treated.
----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.
------------If Acute Renal Insufficiency, The initial treatment for the patient is Bortezomib/Cyclophosphamide/Dexamethasone. After improvement of the renal function, the treatment for the patient is Bortezomib/Lenalidomide/Dexamethasone. With Myeloma therapy done, Perform follow-up/surveillance as follows: [(Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel),(Serum quantitative immunoglobulins, SPEP, and SIFE),(24-h urine for total protein, UPEP, and UIFE at baseline and as clinically indicated or if there is a significant change in FLC levels),(Serum FLC assay),(Whole-body imaging with MRI without contrast, low-dose CT scan, FDG PET/CT annually or as clinically indicated, ideally with the same technique used at diagnosis),(Bone marrow aspirate and biopsy at relapse with FISH as clinically indicated),(Assess for hematopoietic cell transplant candidacy: Refer for evaluation at a hematopoietic cell transplant center. Harvest hematopoietic stem cells (consider for 2 transplants if appropriate),(Consider minimal residual disease (MRD) as indicated for prognostication after shared decision with patient),(See NCCN Guidelines for Survivorship)] After completetion of follow-up/surveillance, analyze for response. Was there a response?
--------------If No, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care.
--------------If Yes, Regardless of transplant or therapy perform follow-up/surveillance by: • Laboratory assessments appropriate for monitoring treatment toxicities may include: CBC, differential, platelet count, blood glucose and electrolytes, and metabolic panel. • Serum quantitative immunoglobulins, SPEP, and SIFE. • 24-h urine for total protein, UPEP, and UIFE at baseline and as needed or if there is a significant change in FLC levels. • Serum FLC assay. • Whole-body advanced imaging with FDG PET/CT, low-dose CT scan, MRI without contrast as needed, ideally with the same technique used at diagnosis. • Bone marrow aspirate and biopsy with multi-parameter flow cytometry as needed. • Consider MRD as indicated for prognostication aftershared decision with patient. Afterwards, is treatment needed for post-transplant or for relapsed/progressive diseases after continuous/maintenance myeloma therapy without prior transplant?
----------------If For Relapsed/progressive diseases without prior transplant, after continuous/maintenance myeloma therapy, Perform therapy for previously treated myeloma or consider a clinical trial. With refractory disease and lack of treatment options, refer to palliative care. 
----------------If For post-transplant, Is it for a Post-autologous hematopoietic cell transplant (single or tandem) or Post-allogeneic hematopoietic cell transplant?
------------------If Post-autologous hematopoietic cell transplant (single or tandem), is it a Progressive disease or a Response/Stable disease?
--------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial or through Allogeneic hematopoietic cell transplant.
--------------------If Response/Stable disease, Perform maintenance therapy (category 1) or a clinical trial. Is the disease now progressive?
----------------------If No, Patient is treated.
----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through clinical trial +/- additional autologous hematopoietic cell transplant or through Allogeneic hematopoietic cell transplant.
------------------If Post-allogeneic hematopoietic cell transplant, is it a Progressive disease or a Response/Stable disease?
--------------------If Progressive disease, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial or through Donor lymphocyte infusion.
--------------------If Response/Stable disease, Perform maintenance therapy on clinical trial or observe. Is the disease now progressive?
----------------------If No, Patient is treated.
----------------------If Yes, Perform additional treatment by therapy for previously treated myeloma, or through a clinical trial through Donor lymphocyte infusion.

